Published On: Wed, Oct 19th, 2016

Heartware International, Inc. (NASDAQ:HTWR) – Broker Update

Below are the most recently updated broker updates which include ratings and price targets for Heartware International, Inc. (NASDAQ:HTWR).

07/13/2016 – Broker: Raymond James Rating: market perform downgrade

07/11/2016 – Broker: Leerink Swann Rating: market perform New Target: 58 downgrade

06/29/2016 – Broker: Barclays Rating: equal-weight New Target: 58 downgrade

06/29/2016 – Broker: BTIG Research Rating: neutral downgrade

06/28/2016 – Broker: SunTrust Rating: neutral New Target: 58 downgrade

06/28/2016 – Broker: Wells Fargo Rating: market perform downgrade

06/27/2016 – Broker: Canaccord Genuity Rating: buy New Target: 66 reiteration

06/08/2016 – Broker: Guggenheim Rating: neutral newcoverage

03/24/2016 – Broker: Bank of America Merrill Lynch Rating: buy upgrade

02/26/2016 – Broker: Northland Securities Rating: market perform New Target: 35 reiteration

01/12/2016 – Broker: JP Morgan Rating: neutral New Target: 39 downgrade

10/30/2015 – Broker: Piper Jaffray Rating: neutral New Target: 44 downgrade

10/14/2015 – Broker: Goldman Sachs Rating: neutral New Target: 42 upgrade

10/13/2015 – Broker: Oppenheimer Rating: perform downgrade

10/02/2015 – Broker: Capital Ideas Research Rating: marketperform reiteration

The average price target from the most recent broker reports is 50.00

The stock increased +0.00% (+0.00) during the last days session, reaching 57.98 and roughly 0 shares were bought or sold by traders. Heartware International, Inc. (NASDAQ:HTWR) has increased by +32.80% over 12 months.

Heartware International, Inc. is a medical device company. The Company develops and manufactures miniaturized implantable heart pumps or ventricular assist devices to treat patients suffering from advanced heart failure. The Company operates in the segment of design and manufacture of medical devices. The HeartWare Ventricular Assist System (HVAD System), which includes a ventricular assist device (VAD) or blood pump, patient accessories and surgical tools, provides circulatory support for patients in the advanced stage of heart failure. The HVAD System is designed to be implanted adjacent to the heart, avoiding abdominal surgery. The HVAD System features the centrifugal pump designed to be implanted in the chest, directly adjacent to the heart. It develops MVAD System, a miniaturized device. The CircuLite Surgical System is designed to be implanted through a right, mini-thoracotomy procedure and does not require a sternotomy or cardiopulmonary bypass.